Welcome to our dedicated page for Elevance Health SEC filings (Ticker: ELV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elevance Health, Inc. filings document formal disclosures for a health benefits and healthcare services company, including Form 8-K reports of quarterly and annual results, earnings guidance, benefit expense ratio updates, and Regulation FD communications. The filings also cover leadership changes, Carelon oversight, board appointments, committee assignments, and executive compensation matters reported through proxy materials.
Its regulatory documents include risk and operating disclosures tied to Health Benefits, Carelon, pharmacy and diversified healthcare services, provider contracting, product mix, government program funding, CMS Star Ratings, litigation, investigations, audits and professional-liability exposure. Recent 8-K disclosures also address CMS oversight of the company's Medicare Advantage-Prescription Drug plans.
Elevance Health, Inc. chief accounting officer and controller Ronald W. Penczek exercised employee stock options for a total of 1,531 shares of common stock and sold 1,531 shares in an open-market transaction at $403.13 per share. Following these transactions, he directly holds 4,109 shares of Elevance Health common stock. The balance includes 10.21 shares acquired earlier through a dividend reinvestment plan.
ELV filed a Form 144 reporting the proposed sale of 1,531 Common shares. The notice lists two stock option exercise entries of 654 and 877 shares, each dated 05/19/2026, and identifies Morgan Stanley Smith Barney LLC as the broker/dealer. The transactions are listed in connection with an Issuer stock option exercise on the NYSE.
STRABLE-SOETHOUT DEANNA D reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health, Inc. director Deanna D. Strable-Soethout received a grant of 563 deferred stock units of common stock as part of the company’s Board of Directors Compensation Program. The award was at no cash cost per unit and brings her reported deferred stock unit holdings to 2,209.
The deferred stock units will be settled in Elevance Health common stock upon the earlier of five years from the grant date or when she ceases to be a board member, unless she has elected a later payout date under the Board of Directors Deferred Compensation Plan.
SCHULMAN AMY W reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health director Amy W. Schulman received an equity award of 563 deferred stock units of common stock under the company’s Board of Directors Compensation Program. This grant increased her directly held equity-related position to 781 shares-equivalent, payable in common stock at a future date tied to service on the board.
Elevance Health director Ryan M. Schneider received an equity grant of 563 deferred stock units of common stock as board compensation. The units were awarded at no cash cost and increase his directly held equity to 7,163 shares. These deferred stock units are scheduled to be settled in Elevance Health common stock on the earlier of five years from the grant date or when he leaves the board, unless he has elected a later distribution date under the company’s Board of Directors Deferred Compensation Plan. This is a routine, compensation-related acquisition rather than an open-market purchase.
PERU RAMIRO G reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health director Ramiro G. Peru received an award of 563 deferred stock units of common stock on May 13. These units were granted at no cash cost as board compensation, increasing his direct holdings to 9,908 shares. The units will be settled in common stock after five years from grant or when he leaves the board, unless he has elected a later payout date.
Neri Antonio F reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health, Inc. director Antonio F. Neri reported receiving a grant of 563 deferred stock units of common stock on May 13, 2026. These units were awarded at no cash cost under the company’s Board of Directors Compensation Program, increasing his direct holdings to 5,488 shares.
The deferred stock units will be settled in Elevance Health common stock upon the earlier of five years from the grant date or when he leaves the board, unless he has elected a later payout date under the Board of Directors Deferred Compensation Plan. This is a routine, compensation-related equity award rather than an open-market purchase.
Elevance Health, Inc. director Bahija Jallal reported an equity compensation grant in the form of deferred stock units tied to the company’s common stock. On the reported date, she acquired 563 shares-equivalent at a stated price of $0.00 per share as a grant or award, not an open-market purchase.
Following this award, Jallal’s direct holdings increased to 5,351 shares of Elevance Health common stock. The footnotes explain that these deferred stock units were accrued under the company’s Board of Directors Compensation Program and will be settled in common stock after a deferral period or when she leaves the board, subject to her prior deferral election.
HAY LEWIS III reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health director Hay Lewis III reported a grant of 563 shares of common stock in the form of deferred stock units. These units were awarded at a price of $0.00 per share as part of the company’s Board of Directors Compensation Program.
Following this award, Lewis directly holds 12,070 shares of Elevance Health common stock. The deferred stock units will be settled in company stock after five years from grant or when he leaves the board, unless he has elected a later payout date under the board’s deferred compensation plan.
Dixon Robert L JR reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health, Inc. director Robert L. Dixon Jr. received a grant of 563 shares of common stock in the form of deferred stock units under the company’s Board of Directors Compensation Program. Following this award, he directly holds 10,885 shares of Elevance Health common stock.
The deferred stock units will be settled in common stock upon the earlier of five years from the grant date or when Dixon ceases to serve on the board, unless he has elected a later payout date under the company’s Board of Directors Deferred Compensation Plan. This is a compensation-related award rather than an open-market purchase.